🇺🇸 FDA
Pipeline program

Asundexian Bayer 10mg Granules, BAY 2433334

21174

Phase 1 small_molecule active

Quick answer

Asundexian Bayer 10mg Granules, BAY 2433334 for Prevention of thromboembolic events is a Phase 1 program (small_molecule) at Bayer AG with 1 ClinicalTrials.gov record(s).

Program details

Company
Bayer AG
Indication
Prevention of thromboembolic events
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials